<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cathepsin L (CTSL) Protein</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">E-64</td>
<td>Irreversible</td>
</tr>
<tr>
<td class="label">CLIK-195</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">CLS-001</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">VBY-825</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">73 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cathepsin L (CTSL) Protein</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">E-64</td>
<td>Irreversible</td>
</tr>
<tr>
<td class="label">CLIK-195</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">CLS-001</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">VBY-825</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">73 edges</a></td>
</tr>
</table>
Cathepsin L (CTSL) is a lysosomal cysteine protease belonging to the papain family that plays essential roles in intracellular protein degradation, antigen processing, and extracellular matrix remodeling. As one of the most potent endopeptidases in mammalian cells, CTSL degrades proteins in the acidic environment of lysosomes and has been increasingly recognized for its involvement in neurodegenerative disease pathogenesis through mechanisms including altered proteolysis, extracellular secretion, and interaction with disease-relevant proteins like amyloid-beta and alpha-synuclein.
Cathepsin L was first characterized in the 1970s as a major lysosomal protease with broad substrate specificity. The enzyme is expressed ubiquitously in mammalian tissues, with highest levels in the liver, kidney, and spleen. Within the central nervous system, CTSL is expressed in neurons, astrocytes, and microglia, where it participates in synaptic protein turnover, myelin degradation, and cellular stress responses[@lysosomal2020].
The importance of CTSL in neurodegeneration has become increasingly apparent as research reveals its dual role: the enzyme can degrade pathological protein aggregates while also generating toxic proteolytic fragments that propagate pathology. This paradoxical function makes CTSL a compelling therapeutic target, as modulating its activity could potentially shift the balance toward beneficial protein clearance[@cathepsin2019].
Cathepsin L is synthesized as a pre-proenzyme consisting of several distinct domains that undergo post-translational processing to yield the mature, active protease[@structure1991]:
CTSL catalyzes peptide bond hydrolysis through a nucleophilic attack mechanism characteristic of cysteine proteases. The catalytic cysteine, with an unusually low pKa (~4.0), remains in its reactive thiolate form at lysosomal pH. Upon substrate binding, the imidazole ring of His159 accepts a proton from the cysteine thiol, enhancing its nucleophilicity. The resulting acyl-enzyme intermediate is then hydrolyzed by a water molecule activated by His159[@catalytic2002].
The substrate specificity of CTSL is relatively broad compared to other cathepsins, with a preference for hydrophobic residues at P2 and P3 positions. This allows CTSL to cleave diverse substrates including:
CTSL undergoes a complex activation cascade beginning with signal peptide removal in the endoplasmic reticulum:
This activation requires the acidic pH of lysosomes (pH 4.5-5.5), which protonates the propeptide and allows autocatalytic cleavage. The mature enzyme is then stable within the lysosomal lumen, where it remains active for extended periods[@biosynthesis1989].
CTSL serves as a major degradative enzyme in the lysosomal system, participating in general protein turnover and selective autophagy. The enzyme contributes to:
CTSL plays a critical role in generating peptide fragments for MHC class II presentation. In antigen-presenting cells:
Under certain conditions, CTSL can be secreted extracellularly, where it degrades matrix proteins and contributes to tissue remodeling. This occurs through:
CTSL is prominently implicated in Alzheimer's disease pathophysiology through multiple mechanisms[@cathepsin2020][@microglial2023]:
Amyloid-Beta Metabolism: CTSL can both degrade amyloid-beta and generate amyloidogenic fragments. The enzyme efficiently cleaves Aβ40 and Aβ42 peptides, particularly oligomeric forms, suggesting a protective role in clearing soluble aggregates. However, CTSL can also cleave the amyloid precursor protein (APP) at sites that favor amyloidogenic processing, potentially increasing Aβ production.
Tau Pathology: CTSL contributes to tau dysfunction through direct cleavage and indirect effects. The enzyme can cleave tau protein, generating fragments that promote aggregation and impair microtubule function. Additionally, CTSL-mediated degradation of tau chaperones may facilitate pathological aggregation.
Microglial Activation: In Alzheimer's disease brain, CTSL is elevated in activated microglia surrounding amyloid plaques. Microglial secretion of CTSL contributes to neuroinflammation and may propagate pathology through extracellular proteolysis.
Cerebrospinal Fluid Biomarkers: CTSL activity is elevated in the cerebrospinal fluid of AD patients, correlating with disease severity. This has led to investigation of CTSL as a potential biomarker for disease progression.
In Parkinson's disease, CTSL participates in several pathogenic processes[@cathepsin2017][@lysosomal2017]:
Alpha-Synuclein Processing: CTSL degrades alpha-synuclein and can generate both protective and toxic fragments. While the enzyme can clear monomeric and oligomeric alpha-synuclein, proteolytic cleavage can also produce truncation products that have enhanced aggregation propensity and are found in Lewy bodies.
Lysosomal Dysfunction: PD-associated mutations in genes like GBA (glucocerebrosidase) impair lysosomal function, reducing CTSL activity and promoting alpha-synuclein accumulation. This creates a feed-forward loop where lysosomal dysfunction promotes protein aggregation.
Dopaminergic Neuron Vulnerability: The substantia nigra of PD patients shows elevated CTSL expression, particularly in dopaminergic neurons undergoing degeneration. This suggests CTSL may contribute to selective neuronal vulnerability.
CTSL is elevated in ALS patient spinal cord and contributes to motor neuron degeneration[@cathepsin2018]:
Protein Aggregate Clearance: CTSL activity is redirected toward degrading protein aggregates in ALS, but the enzyme becomes overwhelmed. Accumulation of misfolded proteins activates the unfolded protein response, contributing to ER stress.
Extracellular Secretion: CTSL is secreted from dying motor neurons and activated glia, where extracellular proteolysis may propagate pathology to neighboring cells.
Invasion of Mononuclear Phagocytes: CTSL activity in immune cells facilitates their invasion of the spinal cord, promoting inflammatory demyelination.
In demyelinating diseases, CTSL plays multiple roles[@cathepsins2013]:
Myelin Basic Protein Degradation: CTSL efficiently degrades myelin basic protein, generating fragments that may serve as autoantigens in autoimmune responses.
Oligodendrocyte Injury: Elevated CTSL in active demyelinating lesions contributes to oligodendrocyte death through protease-mediated injury.
Blood-Brain Barrier Breakdown: CTSL degrades components of the vascular basement membrane, facilitating immune cell entry into the CNS.
The CTSL gene is located on chromosome 9q34.3 and encodes a 375-amino acid pre-proenzyme. The gene structure spans approximately 14 kb and contains 8 exons. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns[@ctsl1996].
Known Polymorphisms: Several single nucleotide polymorphisms in CTSL have been studied for association with neurodegenerative disease risk, though results have been inconsistent across populations.
CTSL expression is regulated at multiple levels:
Several endogenous proteins regulate CTSL activity[@cysteine2022]:
Cystatin C (CST3): The major extracellular inhibitor of CTSL, forming a tight, irreversible complex. CST3 levels are reduced in Alzheimer's disease brain, potentially contributing to increased CTSL activity.
Cystatin B (CSTB): The intracellular inhibitor, particularly important in neurons where it regulates CTSL released from lysosomes during stress.
Pharmaceutical development has produced several CTSL inhibitors:
Inhibitor Development: Selective CTSL inhibitors could reduce pathological extracellular proteolysis while preserving beneficial lysosomal function. Challenges include achieving brain penetration and avoiding immune suppression.
Activity Modulation: Rather than complete inhibition, modulating CTSL activity to promote beneficial proteolysis while blocking harmful extracellular secretion represents an alternative strategy.
Gene Therapy: Viral vector-mediated delivery of CTSL or cystatin constructs could provide localized enzyme modulation.
CTSL shows promise as a biomarker for neurodegenerative diseases[@cathepsin2022a]: